Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-08-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞独立董事关于第二届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors' opinions regarding a specific board meeting agenda item about the use of temporarily idle raised funds for cash management. It references compliance with listing rules and internal company regulations. The document is short (816 characters) and focuses on governance and board-related opinions rather than financial results or detailed reports. It does not contain financial statements or detailed financial data. This fits best under Board/Management Information (MANG), as it relates to board meeting matters and independent directors' opinions on company governance issues.
2022-08-23 Chinese
神州细胞2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, industry analysis, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2022 to June 30, 2022, which is a half-year period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes financial statements, management discussion, and analysis sections, which are characteristic of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-23 Chinese
神州细胞2022年半年度报告摘要
Report Publication Announcement Classification · 95% confidence The document is titled as a '2022 Half-Year Report Summary' (半年度报告摘要) and contains detailed financial data for the half-year period, including total assets, net profit, cash flow, earnings per share, and shareholder information. It explicitly states it is a half-year report summary derived from the full half-year report and advises investors to read the full report on the exchange website. The document length is 3547 characters, which is relatively short and the text mentions it is a summary, not the full report. According to the 'Menu vs Meal' rule, since this is a summary and not the full comprehensive interim report, and it advises to read the full report elsewhere, this document is best classified as a Report Publication Announcement (RPA) rather than the full Interim/Quarterly Report (IR).
2022-08-23 Chinese
神州细胞2022年半年度募集资金存放与实际使用情况的专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022年半年度募集资金存放与实际使用情况的专项报告" which translates to "2022 Half-Year Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their usage, management, and cash management activities for the half-year period ending June 30, 2022. The document includes detailed financial figures related to fundraising and usage, references regulatory guidelines on fundraising management, and provides a table comparing committed and actual investment amounts. The document is a comprehensive report on the use of capital raised by the company during a half-year period, containing substantive financial data and analysis. This fits the definition of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and substantive financial data and analysis related to fundraising and capital usage. It is not merely an announcement or a certification, but a detailed report on fundraising usage for the half-year period. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-23 Chinese
神州细胞关于使用暂时闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory approvals, investment purpose, amount, duration, risk control measures, and opinions from independent directors, supervisors, and the sponsoring institution. The document does not contain financial statements or detailed financial data but is a regulatory announcement about the use of raised funds. It is not an annual or interim report, audit report, or earnings release. It fits the category of a regulatory announcement related to capital use and compliance disclosures. Given the content and length (3122 characters), it is not a full report but an announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-08-23 Chinese
神州细胞第二届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the second meeting of the second Supervisory Board of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes voting results on several agenda items related to the company's 2022 semi-annual report, the use of raised funds, and cash management of temporarily idle raised funds. The document does not contain the actual semi-annual report or detailed financial statements but rather the Supervisory Board's approval and opinions on these matters. It also references that detailed content is available on the Shanghai Stock Exchange website. The document length is short (1674 characters), and it serves as an official announcement of meeting resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain full financial reports or detailed presentations.
2022-08-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.